![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 8
Zeitschriftenartikel
Patel, Anup; Ravaud, Alain; Motzer, Robert J.; Pantuck, Allan J.; Staehler, Michael; Escudier, Bernard; Martini, Jean-Francois; Lechuga, Mariajose; Lin, Xun und George, Daniel J.
(2020):
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
In: Clinical Cancer Research, Bd. 26, Nr. 18: S. 4863-4868
Patel, Anup; Ravaud, Alain; Motzer, Robert J.; Pantuck, Allan J.; Staehler, Michael; Escudier, Bernard; Martini, Jean-Francois; Lechuga, Mariajose; Lin, Xun und George, Daniel J.
(2020):
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.
In: Future Oncology, Bd. 17, Nr. 4: S. 403-409
Rini, Brian I.; Powles, Thomas; Atkins, Michael B.; Escudier, Bernard; McDermott, David F.; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M.; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begona; Porta, Camillo; Melichar, Bohuslav; Gurney, Howard; Bedke, Jens; Choueiri, Toni K.; Parnis, Francis; Khaznadar, Tarik; Thobhani, Alpa; Li, Shi; Piault-Louis, Elisabeth; Frantz, Gretchen; Huseni, Mahrukh; Schiff, Christina; Green, Marjorie C. und Motzer, Robert J.
(2019):
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
In: Lancet, Bd. 393, Nr. 10189: S. 2404-2415
Bracarda, Sergio; Bamias, Aristotelis; Casper, Jochen; Negrier, Sylvie; Sella, Avishay; Staehler, Michael; Tarazi, Jamal; Felici, Alessandra; Rosbrook, Brad; Jardinaud-Lopez, Monica und Escudier, Bernard
(2019):
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
In: Clinical Genitourinary Cancer, Bd. 17, Nr. 3, E689-E703
George, Daniel J.; Martini, Jean-Francois; Staehler, Michael; Motzer, Robert J.; Magheli, Ahmed; Donskov, Frede; Escudier, Bernard; Li, Sherry; Casey, Michelle; Valota, Olga; Laguerre, Brigitte; Pantuck, Allan J.; Pandha, Hardev S.; Patel, Anup; Lechuga, Maria und Ravaud, Alain
(2019):
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
In: Clinical Cancer Research, Bd. 25, Nr. 4: S. 1165-1173
Motzer, Robert J.; Ravaud, Alain; Patard, Jean-Jacques; Pandha, Hardev S.; George, Daniel J.; Patel, Anup; Chang, Yen-Hwa; Escudier, Bernard; Donskov, Frede; Magheli, Ahmed; Carteni, Giacomo; Laguerre, Brigitte; Tomczak, Piotr; Breza, Jan; Gerletti, Paola; Lechuga, Mariajose; Lin, Xun; Casey, Michelle; Serfass, Lucile; Pantuck, Allan J. und Stähler, Michael
(2018):
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
In: European Urology, Bd. 73, Nr. 1: S. 62-68
Schoffski, Patrick; Wozniak, Agnieszka; Escudier, Bernard; Rutkowski, Piotr; Anthoney, Alan; Bauer, Sebastian; Sufliarsky, Jozef; Herpen, Carla van; Lindner, Lars H.; Grünwald, Viktor; Zakotnik, Branko; Lerut, Evelyne; Debiec-Rychter, Maria; Marreaud, Sandrine; Lia, Michela; Raveloarivahy, Tiana; Collette, Sandra und Albiges, Laurence
(2017):
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
In: European Journal of Cancer, Bd. 87: S. 147-163
Powles, Thomas; Lackner, Mark R.; Oudard, Stéphane; Escudier, Bernard; Ralph, Christy; Brown, Janet E.; Hawkins, Robert E.; Castellano, Daniel; Rini, Brian I.; Staehler, Michael D.; Ravaud, Alain; Lin, Wei; O'Keeffe, Bridget; Wang, Yulei; Lu, Shan; Spoerke, Jill M.; Huw, Ling-Yuh; Byrtek, Michelle; Zhu, Rui; Ware, Joseph A. und Motzer, Robert J.
(2016):
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
In: Journal of Clinical Oncology, Bd. 34, Nr. 14:
1660-U204